AtrionATRI
Market Cap: 805M
About: Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Employees: 712
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
33% more capital invested
Capital invested by funds: $438M [Q4 2023] → $580M (+$143M) [Q1 2024]
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
5.45% more ownership
Funds ownership: 65.69% [Q4 2023] → 71.14% (+5.45%) [Q1 2024]
2% more funds holding
Funds holding: 112 [Q4 2023] → 114 (+2) [Q1 2024]
5% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 37
Research analyst outlook
We haven’t received any recent analyst ratings for ATRI.
Financial journalist opinion
Based on 6 articles about ATRI published over the past 30 days